Delisting risk
Quantum-Si (QSI)
Builds benchtop systems, kits, and software for research-use protein sequencing.
$0.7676
Pre-market+0.00 (+0.04%)
At close$0.7673(+1.32%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 27 | 28 | 24 | 27 | 28 | 31 | 26 | 27 | 25 | 21 | 24 | 26 | |
| Research & development | 17 | 16 | 12 | 14 | 16 | 17 | 14 | 15 | 14 | 11 | 14 | 16 |
| 11 | 12 | 12 | 12 | 12 | 14 | 12 | 12 | 11 | 10 | 10 | 10 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Operating income | −27 | −28 | −23 | −26 | −28 | −31 | −25 | −27 | −24 | −21 | −24 | −26 |
| 2 | 6 | 4 | 3 | 3 | −2 | 6 | −2 | −11 | 3 | 2 | 2 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 |
| Other non-operating income | 0 | −15 | −4 | −3 | −3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −25 | −22 | −19 | −23 | −25 | −33 | −19 | −29 | −36 | −18 | −22 | −24 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −25 | −22 | −19 | −23 | −25 | −33 | −19 | −29 | −36 | −18 | −22 | −24 |
| Net income | −25 | −22 | −19 | −23 | −25 | −33 | −19 | −29 | −36 | −18 | −22 | −24 |
| EPS, basic | −$0.17 | −$0.16 | −$0.14 | −$0.16 | −$0.18 | −$0.23 | −$0.11 | −$0.16 | −$0.17 | −$0.08 | −$0.10 | −$0.11 |
| EPS, diluted | −$0.17 | −$0.16 | −$0.14 | −$0.16 | −$0.18 | −$0.23 | −$0.11 | −$0.16 | −$0.17 | −$0.08 | −$0.10 | −$0.11 |
| Weighted average shares, basic | 142 | 142 | 142 | 142 | 142 | 146 | 182 | 184 | 209 | 198 | 216 | 218 |
| Weighted average shares, diluted | 142 | 142 | 142 | 142 | 142 | 146 | 182 | 184 | 209 | 198 | 216 | 218 |
| EBITDA | −26 | −12 | −18 | −22 | −24 | −32 | −24 | −26 | −23 | −20 | −23 | −26 |
| Depreciation & amortization | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| EBIT | −27 | −13 | −19 | −23 | −25 | −33 | −25 | −27 | −24 | −21 | −24 | −26 |
